Stock Price, News, Quote and Profile of ENTERA BIO LTD(NASDAQ:ENTX) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ENTERA BIO LTD

NASDAQ:ENTX (5/1/2024, 3:30:02 PM)

+0.04 (+2.04%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap70.96M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Company Info

ENTERA BIO LTD

Hadassah / Jerusalem Bio, Park, 5th Floor

JERUSALEM 9112002

P: 97225327151

CEO: Spiros Jamas

Employees: 19

Website: https://enterabio.com/

ENTX News

16 days ago - InvestorPlaceCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?

Discover three biotech stocks with explosive growth potential. Don't miss out on these great picks this year.

23 days ago - Entera Bio Ltd.Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...

a month ago - Entera Bio Ltd.Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered...

2 months ago - Entera Bio Ltd.Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...

2 months ago - Entera Bio Ltd.Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

JERUSALEM, March 04, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...

3 months ago - Seeking AlphaEntera Bio files to sell 16.5M ordinary shares for holders (NASDAQ:ENTX)

Learn about Entera Bio's recent filing of a prospectus for the offer and resale of up to 16,500,894 shares of its ordinary shares by selling shareholders.

ENTERA BIO LTD (ENTX)

Nasdaq Stock Screener

USA Stock Screener